"Hyperparathyroidism, Secondary/drug therapy"[MAJR] - Search Results

Year	Number of Results
1968	1
1969	1
1970	1
1972	4
1973	10
1974	6
1975	9
1976	21
1977	24
1978	21
1979	11
1980	24
1981	12
1982	16
1983	10
1984	6
1985	12
1986	9
1987	7
1988	6
1989	8
1990	9
1991	13
1992	18
1993	12
1994	25
1995	27
1996	25
1997	16
1998	18
1999	17
2000	19
2001	11
2002	25
2003	44
2004	39
2005	57
2006	50
2007	49
2008	74
2009	53
2010	47
2011	69
2012	62
2013	48
2014	41
2015	49
2016	48
2017	52
2018	44
2019	44
2020	38
2021	30
2022	46
2023	28
2024	31
2025	23

1

Advances in the treatment of secondary and tertiary hyperparathyroidism.

Zhang LX, Zhang B, Liu XY, Wang ZM, Qi P, Zhang TY, Zhang Q. Zhang LX, et al. Front Endocrinol (Lausanne). 2022 Dec 6;13:1059828. doi: 10.3389/fendo.2022.1059828. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36561571 Free PMC article. Review.

2

Vitamin D and Secondary Hyperparathyroidism in Chronic Kidney Disease: A Critical Appraisal of the Past, Present, and the Future.

Brandenburg V, Ketteler M. Brandenburg V, et al. Nutrients. 2022 Jul 22;14(15):3009. doi: 10.3390/nu14153009. Nutrients. 2022. PMID: 35893866 Free PMC article. Review.

3

Upacicalcet: First Approval.

Hoy SM. Hoy SM. Drugs. 2021 Sep;81(13):1593-1596. doi: 10.1007/s40265-021-01578-y. Drugs. 2021. PMID: 34390486 Review.

4

[Secondary hyperparathyroidism--treatment review].

Graczyk M. Graczyk M. Wiad Lek. 2015;68(2):179-82. Wiad Lek. 2015. PMID: 26181154 Review. Polish.

5

Effectiveness of calcimimetics on fractures in dialysis patients with secondary hyperparathyroidism: meta-analysis of randomized trials.

Wakamatsu T, Yamamoto S, Matsuo K, Taniguchi M, Hamano T, Fukagawa M, Kazama JJ. Wakamatsu T, et al. J Bone Miner Metab. 2024 May;42(3):316-325. doi: 10.1007/s00774-024-01500-y. Epub 2024 Mar 27. J Bone Miner Metab. 2024. PMID: 38536478

6

Cinacalcet hydrochloride.

Barman Balfour JA, Scott LJ. Barman Balfour JA, et al. Drugs. 2005;65(2):271-81. doi: 10.2165/00003495-200565020-00007. Drugs. 2005. PMID: 15631545 Review.

7

The cost-effectiveness of drug therapies to treat secondary hyperparathyroidism in renal failure: a focus on evidence regarding paricalcitol and cinacalcet.

Lorenzoni V, Trieste L, Turchetti G. Lorenzoni V, et al. Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):611-24. doi: 10.1586/14737167.2015.1047348. Epub 2015 May 17. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 25988877 Review.

8

Treatment of secondary hyperparathyroidism: How do cinacalcet and etelcalcetide differ?

Eidman KE, Wetmore JB. Eidman KE, et al. Semin Dial. 2018 Sep;31(5):440-444. doi: 10.1111/sdi.12734. Epub 2018 Jul 15. Semin Dial. 2018. PMID: 30009474 Review.

9

Nephrology picture: bone loss due to absence of adequate therapy for severe secondary hyperparathyroidism.

Duque EJ, Elias RM, Jorgetti V, Moysés RMA. Duque EJ, et al. J Nephrol. 2022 Dec;35(9):2445-2447. doi: 10.1007/s40620-022-01496-6. Epub 2022 Nov 1. J Nephrol. 2022. PMID: 36319936 Free PMC article. No abstract available.

10

Advances in pharmacotherapy for secondary hyperparathyroidism.

Rodríguez M, Rodríguez-Ortiz ME. Rodríguez M, et al. Expert Opin Pharmacother. 2015;16(11):1703-16. doi: 10.1517/14656566.2015.1061994. Expert Opin Pharmacother. 2015. PMID: 26159447 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,387 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,387 results

Results by year